title: [A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
abstract: We report a 47-year-old female patient who was suffering from severe DIC due to multiple bone metastases. This patient was treated weekly with an intraarterial 5-FU (500 mg) and MTX (100 mg) including AT-II by a subcutaneously implanted port system placed into her abdominal aorta. Furthermore, she was administered tegafur/uracil (400 mg/day) 5 days weekly for pharmacokinetic modulating chemotherapy (PMC). After three courses of PMC treatment, DIC was resolved and the tumor marker was reduced. However, after 22 courses of this regimen, DIC suddenly recurred. As second line chemotherapy, we then administered paclitaxel (80 mg) in place of CDDP. After five courses of this second line chemotherapy, DIC recovered and the tumor marker was again decreased. We concluded that this chemotherapy is effective for advanced gastric cancer complicated with bone metastasis and DIC from the standpoint of toxicities, antitumor effect and QOL of the patient.
authors.affiliation: Dept of Gastroenterology, Saiseikai Niigata Second Hospital.
authors.forename: Toru
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Mizuno
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Togashi
authors.forename: Kouji
authors.initials: K
authors.lastname: Watanabe
authors.forename: Keiichi
authors.initials: K
authors.lastname: Seki
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohta
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Tomoteru
authors.initials: T
authors.lastname: Kamimura
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D018279:Carcinoma, Signet Ring Cell / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015918:Infusion Pumps, Implantable; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D000804:Angiotensin II; D005641:Tegafur; D014498:Uracil; D017239:Paclitaxel; D005472:Fluorouracil; D008727:Methotrexate